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The opioid receptors are categorized into three types (µ, δ, and 
κ) and each type displays its various pharmacological effects. The 
κ opioid receptor (KOR) agonists are believed to be applicable to 
analgesia, diuresis, treatment of drug dependence and uremic 
pruritus.1 Since the discovery of the first nonpeptidic KOR agonist 
U-50,488 in the early 1980s,2 KOR agonists have been intensively 
sought by many medicinal chemists and were revealed to exert 
undesirable side effects including sedation3 and psychotomimetic 
effects4, 5 at effective doses. The nonpeptidic KOR agonists have 
been classified into seven types: 1) benzomorphan derivatives 
including bremazocine, 2) morphinan derivatives including 
nalfurafine, 3) arylacetamide derivatives including U-50,488 and 
U-69,593, 4) diazabicyclononanone derivatives including HZ2, 5) 
bicyclic guanidine derivatives including TPI 614-1, 6) 
benzodiazepine derivatives including tifluadom, and 7) 
neoclerodane diterpene derivatives including salvinorin A.6 The 
KOR agonist nalfurafine hydrochloride (TRK- 820) was launched 
in Japan as an antipruritic for dialysis patients and this drug 
exhibited neither aversive nor addictive effects at effective doses.1 
Nalfurafine is characterized by the structural feature of a 
phenethylamine unit, a common structure observed in endogenous 
opioid peptides such as enkephalins, dynorphins, and β-endorphin. 
Recently, a diphenethylamine derivative HS665 was reported as a 
selective KOR agonist by Schmidhammer et al.7 We also reported 
that a 1,3,5-trioxazatriquinane derivative 
SYK-146 (1) with m-hydroxyphenyl groups, which also included 
the phenethylamine moiety, was a selective KOR agonist and that 
its eutomer (-)-SYK-146 exhibited dose-dependent 
antinociceptive effects in the mouse acetic acid writhing test.8 
The structure-activity relationship (SAR) investigation of SYK- 
146 derivatives with m-hydroxyphenyl groups suggested that the 
hydroxy groups on the phenyl rings would be the significant 
structural motif for exerting the KOR agonistic activity. 
Therefore, we planned to investigate the effect of the position of 
the hydroxy groups on the KOR agonistic activity. Herein, we 
report the synthesis of 1,3,5-trioxazatriquinane derivatives with 
o- or p-hydroxyphenyl groups and their in vitro pharmacological 
properties. 
According to the previously reported method,8 we prepared 
1,3,5-trioxazatriquinanes 13a-c and 17a-d with o-hydroxyphenyl 
groups. The synthesis of 13a-c commenced with o-
methoxyacetophenone (2). α-Hydroxyaldehyde 5 and its  
Figure 1. Structure of SYK-146. 
 






We designed and synthesized of 1,3,5-trioxazatriquinanes with o- or p-hydroxyphenyl rings as 
analogs of the κ opioid receptor agonist SYK-146 with m-hydroxyphenyl groups. Although 
almost all tested compounds did not bind to the opioid receptors, only 17b with two o-
hydroxyphenyl rings showed moderate or potent binding affinities and exhibited agonistic 
activities for three opioid receptor types. Because the basicity of the nitrogen atom in the 1,3,5-
trioxazatriquinane structure was predicted to be very low due to the electron withdrawing effect 
of three oxygen atoms, 17b was a novel non-morphinan and nonpeptidic opioid universal 
agonist lacking a basic nitrogen atom. 
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Scheme 1. Reagents and conditions; (a) TosMIC, K2CO3, MeOH, rt; (b) 2 M HCl aq, THF, rt; (c) p-Methoxyphenyl magnesium bromide, THF,  0 °C to rt; (d) 
AcOH, H2O, reflux; (e) NH4Cl, AcONa, MeOH, reflux; (f) 5, 7, CSA, ClCH2CH2Cl, reflux; (g) 6, 8, CSA, CHCl3, rt, 2 weeks, 11a: 17%, 11b: 19%, 11c: 7% 
from 2, 12a: 7%, 12b: 10%, 12c: 8% from 3; (h) 1-Propanethiol, t-BuOK, DMF, 130°C, 13a: 71% from 11a, 13b: 71% from 11b, 13c: 55% from 11c, 14a: 73% 
from 12a, 14b: 73%  from 12b, 14c: 67% from 12c. 
Scheme 2. Reagents and conditions; (a) glycolaldehyde dimer, CSA, CHCl3, reflux 15a: 20%, 15b: 6%, 15c: 12%, 15d: 7% from 2, 16a: 16%, 16b: 13%, 16c: 
14%, 16d: 5% from 4;  (b) 1-propanethiol, t-BuOK, DMF, 130 °C, 17a: quant from 15a, 17b: quant from 15b, 17c: quant from 15c, 17d: quant from 15d, 18a: 
87% from 16a, 18b: 91% from 16b, 18c: quant from 16c, 18d: 60% from 16d. 
hemiacetal dimer 7 derived from 2 were treated with ammonium  
chloride and sodium acetate to give oxazoline 9. Oxazoline 9 
reacted with the mixture of 5 and 7 in the presence of 
camphorsulfonic acid (CSA) to provide 11a-c (Scheme 1). An 
attempt to synthesize 6 and 8 with p-methoxyphenyl groups by 
the same synthetic method of 5 and 7 furnished a recovery of 
starting materials. Therefore, 6 and 8 were prepared by a reaction 
of pyruvic aldehyde dimethyl acetal (3) with p-
methoxyphenylmagnesium bromide and subsequent hydrolysis 
of acetal 4. The resulting mixture of 6 and 8 was treated with 
ammonium chloride and sodium acetate in MeOH under reflux 
to afford oxazoline 10. Oxazoline 10 was treated with the 
mixture of 6 and 8 in the presence of CSA to provide 12a-c 
(Scheme 1). Derivatives 15a-d or 16a-d having two identical 
aryl units were prepared by the acidic condensation of 9 or 10 
with glycolaldehyde dimer, respectively (Scheme 2). The key 
intermediates of the synthesis of 1,3,5-
trioxazatriquinane derivatives 21a, b and 22a, b were the 
respective oxazolines 19 and 20. Ketone 2 was treated with 
p-toluenesulfonylmethyl isocyanide (TosMIC) at rt in the 
presence of potassium carbonate, followed by hydrolysis 
with 2 M HCl, subsequent addition of hexamethyldisilazane 
(HMDS) for neutralization, and then treatment with 
ammonium chloride and sodium acetate in MeOH at rt to give 
oxazoline 19. Oxazoline 20 was prepared from acetal 4 by 
sequential treatments similar to those of 19. 1,3,5-
Trioxazatriquinanes with a methoxyphenyl group 21a, b or 22a, 
b were prepared by the acidic condensation of 19 or 20 with 
glycolaldehyde dimer, respectively (Scheme 3).  
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Scheme 3. Reagents and conditions; (a) TosMIC, K2CO3, MeOH, rt; (b) 2 M HCl aq, MeOH, rt, then HMDS, glycolaldehyde dimer, NH4Cl, AcONa, MeOH, rt; 
(c) p-Methoxyphenyl Grignard reagent, THF,  0 °C to rt; (d) AcOH, H2O, reflux, then HMDS, glycolaldehyde dimer, NH4Cl, AcONa, MeOH, rt; (e) 
glycolaldehyde dimer, CSA, CHCl3, reflux, 21a: 34%, 21b: 20% from 2, 22a: 27%, 22b: 16% from 3; (f)1-propanethiol, t-BuOK, DMF, 130 °C, 23a: 84% from 
21a, 23b: 76% from 21b, 24a: 84% from 22a, 24b: 76% from 22b. 
Table 1. Binding affinities of 1,3,5-trioxazatriquinane 
derivatives for opioid receptors.a 
a Binding assays were carried out in duplicate (MOR and 
DOR: whole brain without cerebellum of mouse, KOR: 
cerebellum of guinea pig).
b [3H]DAMGO was used. 
c [3H]DPDPE was used. 
d [3H]U-69,593 was used. 
e N.T.: not tested 
f Ref. 8
Table 2. Agonist activities of 1,3,5-trioxazatriquinane 
derivatives for opioid receptors.a 
a [35S] GTPγS binding assays were carried out in duplicate 
using human MOR, DOR, or KOR expressed CHO cells. 
DAMGO, DPDPE, or U-69,593 was used as the standard MOR, 
DOR, or KOR agonist, respectively.
b N.T.: not tested 
c N.D.: not detected 
d Ref. 8 
The O-methyl groups of thus prepared 1,3,5-trioxazatriquinanes 
11a-c, 12a-c, 15a-d, 16a-d, 21a, b and 22a, b9 were removed by 
a treatment with a potassium thiolate to afford the corresponding 
compounds 13a-c, 14a-c, 17a-d, 18a-d, 23a, b and 24a, b, 
respectively.  
   The binding affinities of the synthesized 
1,3,5-trioxazatriquinanes for the opioid receptors were 
evaluated with competitive binding assays (Table 1). Assays 
were performed by a previously reported procedure.8 
Although almost all tested compounds showed no binding 
affinities to the opioid receptors, 17b alone, with two o-
hydroxyphenyl groups, bound to the opioid receptors. This 
tendency was observed in the series of 1,3,5-
trioxazatriquinanes with m-hydroxyphenyl groups: mono or 
trisubstituted 1,3,5-trioxazatriquinane derivatives did not bind 
to the opioid receptors due to the absence of a pharmacophore 
unit (the second hydroxyphenyl group) or the steric hindrance 
of the third hydroxyphenyl group. Among the disubstituted 
1,3,5-trioxazatriquinanes, only one of the derivatives 
demonstrated remarkable binding to the opioid receptors. 
Contrary to 1, which had a selective and strong binding affinity 
to the KOR, 17b with 
Ki (nM) 
MORb DORc KORd 
DAMGO 0.83 N.T. e N.T. e 
DPDPE N.T.e 0.90 N.T. e 
U-69,593 > 1000 > 1000 1.37 
SYK-146 (1)f > 1000 > 1000 6.09 
13a > 1000 > 1000 > 1000 
13b > 1000 > 1000 > 1000 
13c > 1000 > 1000 > 1000 
14a > 1000 > 1000 > 1000 
14b > 1000 > 1000 > 1000 
14c > 1000 > 1000 > 1000 
17a > 1000 > 1000 > 1000 
17b 20.5 88.8 9.17 
17c > 1000 > 1000 > 1000 
17d > 1000 > 1000 > 1000 
18a > 1000 > 1000 > 1000 
18b > 1000 > 1000 > 1000 
18c > 1000 > 1000 > 1000 
18d > 1000 > 1000 > 1000 
23a > 1000 > 1000 > 1000 
23b > 1000 > 1000 > 1000 
24a > 1000 > 1000 > 1000 
24b > 1000 > 1000 > 1000 
EC50 (Emax) 




N.T. b N.T. b 




U-69,593 N.T. b N.T. b 
8.03 nM 
(100%) 
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two o-hydroxyphenyl groups exhibited moderate binding 
affinities to the µ opioid receptor (MOR) and the δ opioid receptor 
(DOR) with Ki values of 20.5 and 88.8 nM, respectively. 
Furthermore, 17b also strongly bound to the KOR with a Ki value 
of 9.17 nM. It is noteworthy that the configuration of 17b was 
different from that of 1. The functional activities of 17b were 
assessed by [35S] GTPγS binding assays with human opioid 
receptor-transfected CHO cells. Previously reported procedures8 
were used. Compound 17b showed universal agonistic activities 
to the opioid receptors (Table 2). Although many ligands have 
been reported to bind nonselectively to the opioid receptor 
types,10 most of them were universal antagonists or agonist/
antagonists.11 To the best of our knowledge, a few ligands have 
shown universal agonistic activities, for example etorphine, (-)-
ethylketocyclazocine.10 It is interesting that 17b exhibited a more 
potent and efficacious agonistic activity for the KOR than did 1. 
Until the discovery of salvinorin A as a KOR agonist,12, 13 the 
basic nitrogen was believed to be the essential structural 
determinant for binding to the opioid receptor. The salvinorin A 
derivative herkinorin was reported to be an MOR agonist 
possessing no basic nitrogen atom.13-15 17b may also be an opioid 
agonist lacking the basic nitrogen because the basicity of the 
nitrogen in 1,3,5-trioxazatriquinanes was predicted to be low due 
to the electron withdrawing effect of the three oxygen atoms. 
Indeed, the pKa value of 17b was calculated to be 3.42 by 
ADMET Predictor.16,17 17b was a potent KOR agonist comparable 
to salvinorin A (EC50 value: 40 nM, Emax: 120%) and a more 
potent MOR agonist than herkinorin (EC50 value: 500 nM, Emax: 
130%).14 Future investigations of the binding mode of 17b to the 
opioid receptor types would shed light on the role and necessity 
of the basic nitrogen in the opioid agonists. Our results also 
indicated that the substitution position of the hydroxyl group 
would remarkably affect the in vitro pharmacological profiles of 
1,3,5-trioxazatriquinanes. We are now exploring the binding 
mode of 17b. 
 In summary, we have designed and synthesized the 1,3,5-
trioxazatriquinane derivatives with o- or p-hydroxyphenyl groups. 
Among the synthesized compounds, 17b exhibited moderate 
binding affinities to the MOR and the DOR, and strong binding 
affinity to the KOR. Furthermore, 17b showed universal 
agonistic activities to the three opioid receptor types. These 
results suggest that 17b is a novel non-morphinan and 
nonpeptidic opioid universal agonist lacking a basic nitrogen 
atom. 
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